These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 30514777)

  • 41. MGMT Status as a Clinical Biomarker in Glioblastoma.
    Butler M; Pongor L; Su YT; Xi L; Raffeld M; Quezado M; Trepel J; Aldape K; Pommier Y; Wu J
    Trends Cancer; 2020 May; 6(5):380-391. PubMed ID: 32348734
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.
    McAleenan A; Kelly C; Spiga F; Kernohan A; Cheng HY; Dawson S; Schmidt L; Robinson T; Brandner S; Faulkner CL; Wragg C; Jefferies S; Howell A; Vale L; Higgins JPT; Kurian KM
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013316. PubMed ID: 33710615
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimal treatment strategy for adult patients with newly diagnosed glioblastoma: a systematic review and network meta-analysis.
    Jin L; Guo S; Zhang X; Mo Y; Ke S; Duan C
    Neurosurg Rev; 2021 Aug; 44(4):1943-1955. PubMed ID: 33037945
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma.
    Nguyen N; Redfield J; Ballo M; Michael M; Sorenson J; Dibaba D; Wan J; Ramos GD; Pandey M
    CNS Oncol; 2021 Sep; 10(3):CNS74. PubMed ID: 34486380
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment considerations for MGMT-unmethylated glioblastoma.
    Taylor JW; Schiff D
    Curr Neurol Neurosci Rep; 2015 Jan; 15(1):507. PubMed ID: 25394859
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients.
    Radke J; Koch A; Pritsch F; Schumann E; Misch M; Hempt C; Lenz K; Löbel F; Paschereit F; Heppner FL; Vajkoczy P; Koll R; Onken J
    Acta Neuropathol Commun; 2019 Jun; 7(1):89. PubMed ID: 31167648
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma.
    Wick A; Kessler T; Platten M; Meisner C; Bamberg M; Herrlinger U; Felsberg J; Weyerbrock A; Papsdorf K; Steinbach JP; Sabel M; Vesper J; Debus J; Meixensberger J; Ketter R; Hertler C; Mayer-Steinacker R; Weisang S; Bölting H; Reuss D; Reifenberger G; Sahm F; von Deimling A; Weller M; Wick W
    Neuro Oncol; 2020 Aug; 22(8):1162-1172. PubMed ID: 32064499
    [TBL] [Abstract][Full Text] [Related]  

  • 48. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.
    Rivera AL; Pelloski CE; Gilbert MR; Colman H; De La Cruz C; Sulman EP; Bekele BN; Aldape KD
    Neuro Oncol; 2010 Feb; 12(2):116-21. PubMed ID: 20150378
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patterns of care and outcomes of chemoradiation versus radiation alone for MGMT promoter unmethylated glioblastoma.
    Lee A; Malakhov N; Sheth N; Wang A; Han P; Schreiber D
    Clin Neurol Neurosurg; 2018 Jul; 170():127-131. PubMed ID: 29777945
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
    Stupp R; Hegi ME; Gorlia T; Erridge SC; Perry J; Hong YK; Aldape KD; Lhermitte B; Pietsch T; Grujicic D; Steinbach JP; Wick W; Tarnawski R; Nam DH; Hau P; Weyerbrock A; Taphoorn MJ; Shen CC; Rao N; Thurzo L; Herrlinger U; Gupta T; Kortmann RD; Adamska K; McBain C; Brandes AA; Tonn JC; Schnell O; Wiegel T; Kim CY; Nabors LB; Reardon DA; van den Bent MJ; Hicking C; Markivskyy A; Picard M; Weller M; ; ;
    Lancet Oncol; 2014 Sep; 15(10):1100-8. PubMed ID: 25163906
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA.
    Lee JY; Park CK; Park SH; Wang KC; Cho BK; Kim SK
    Childs Nerv Syst; 2011 Nov; 27(11):1877-83. PubMed ID: 21789683
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
    Gilbert MR; Wang M; Aldape KD; Stupp R; Hegi ME; Jaeckle KA; Armstrong TS; Wefel JS; Won M; Blumenthal DT; Mahajan A; Schultz CJ; Erridge S; Baumert B; Hopkins KI; Tzuk-Shina T; Brown PD; Chakravarti A; Curran WJ; Mehta MP
    J Clin Oncol; 2013 Nov; 31(32):4085-91. PubMed ID: 24101040
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients.
    McDonald KL; Rapkins RW; Olivier J; Zhao L; Nozue K; Lu D; Tiwari S; Kuroiwa-Trzmielina J; Brewer J; Wheeler HR; Hitchins MP
    Eur J Cancer; 2013 Jan; 49(2):360-8. PubMed ID: 22975219
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The different role of YKL-40 in glioblastoma is a function of MGMT promoter methylation status.
    Chen WJ; Zhang X; Han H; Lv JN; Kang EM; Zhang YL; Liu WP; He XS; Wang J; Wang GH; Yu YB; Zhang W
    Cell Death Dis; 2020 Aug; 11(8):668. PubMed ID: 32820151
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.
    Jung TY; Jung S; Moon KS; Kim IY; Kang SS; Kim YH; Park CS; Lee KH
    Oncol Rep; 2010 May; 23(5):1269-76. PubMed ID: 20372840
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
    Ishii D; Natsume A; Wakabayashi T; Hatano H; Asano Y; Takeuchi H; Shimato S; Ito M; Fujii M; Yoshida J
    Neurol Med Chir (Tokyo); 2007 Aug; 47(8):341-9; discussion 350. PubMed ID: 17721049
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma.
    Seystahl K; Hentschel B; Loew S; Gramatzki D; Felsberg J; Herrlinger U; Westphal M; Schackert G; Thon N; Tatagiba M; Pietsch T; Reifenberger G; Löffler M; Wick W; Weller M;
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):659-670. PubMed ID: 31754832
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study.
    Annavarapu S; Gogate A; Pham T; Davies K; Singh P; Robert N
    CNS Oncol; 2021 Sep; 10(3):CNS76. PubMed ID: 34378977
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
    Hegi ME; Diserens AC; Godard S; Dietrich PY; Regli L; Ostermann S; Otten P; Van Melle G; de Tribolet N; Stupp R
    Clin Cancer Res; 2004 Mar; 10(6):1871-4. PubMed ID: 15041700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.